Evidence map›Paper›PMID 41973737›Full record

ReviewDiabetes care2026

Clinical Potential of GIP in Type 2 Diabetes and Obesity.

Michael Nauck, Fiona Gribble, Frank Reimann, David A D'Alessio, Jonathan E Campbell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Michael NauckDiabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum, Sankt Josef-Hospital, Ruhr-University, Bochum, Germany.ORCID 0000-0002-5749-6954
Fiona GribbleInstitute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.ORCID 0000-0002-4232-2898
Frank ReimannInstitute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.
David A D'AlessioDuke Molecular Physiology Institute, Durham, NC.
Jonathan E CampbellDuke Molecular Physiology Institute, Durham, NC.ORCID 0000-0003-4358-6331

Funding

NIDDK NIH HHS DK046492NIDDK NIH HHS DK132324NIDDK NIH HHS DK141090NIDDK NIH HHS DK143978NIDDK NIH HHS P30-K124723
6 · The paper itself

Abstract

Incretin-based pharmacology has revolutionized the medical treatment of type 2 diabetes and obesity. The most effective drug to date is tirzepatide, a dual incretin receptor agonist that engages both the glucagon-like peptide 1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). While the relative contributions of GIPR and GLP-1R actions to the clinical effects of tirzepatide have not been established, the potency of this agent has reignited interest in the clinical potential of GIPR agonism. Here, we discuss incretin biology as it relates to metabolic pharmacology and contextualize the mechanisms by which GIPR activity could contribute to the development of new and effective drugs. We explore current and future applications of GIPR agonists and antagonists, to underscore the potential that this signaling system could add to treatment of type 2 diabetes and obesity.

Indexed as

Diabetes Mellitus, Type 2Gastric Inhibitory PolypeptideObesityAnimalsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansIncretinsReceptors, Gastrointestinal HormoneTirzepatideGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsReceptors, Gastrointestinal HormoneTirzepatide

Identifiers

PMID41973737
PMCPMC13385947

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.